Physician profile
Bob Geng
NPI 1356570758
$3,316,479.47
in general payments reported to CMS, 2019-2025
69 companies · $760K in 2025
The $760K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $169K · 2020: $108K · 2021: $339K · 2022: $641K · 2023: $732K · 2024: $566K · 2025: $760K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.3M · Travel and Lodging: $363K · Consulting Fee: $234K · Food and Beverage: $63K · Honoraria: $53K · Education: $9,062 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,333,589.81 |
| Travel and Lodging | $363,290.68 |
| Consulting Fee | $233,505.79 |
| Food and Beverage | $63,088.17 |
| Honoraria | $53,000.00 |
| Education | $9,061.69 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $630,605.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $566,153.87 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $499,792.05 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $214,225.49 | 2020-2025 | Xembify |
| Abbvie INC. | $187,838.77 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $179,476.72 | 2020-2025 | Takhzyro, Cinryze, Hyqvia |
| Pfizer INC. | $111,469.01 | 2019-2025 | |
| Horizon Therapeutics Plc | $100,700.13 | 2019-2023 | Actimmune |
| Biocryst US Sales Co., LLC | $89,330.64 | 2021-2025 | Orladeyo |
| Incyte Corporation | $79,139.26 | 2021-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $78,326.30 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Adma Biomanufacturing LLC | $57,695.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $47,975.98 | 2019-2025 | Ilaris |
| Pharming Healthcare, INC. | $43,318.28 | 2020-2025 | Joenja, Ruconest |
| Shire North American Group INC | $41,534.14 | 2019 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $37,990.14 | 2023-2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $37,729.03 | 2019-2025 | |
| Amgen INC. | $36,369.10 | 2021-2025 | Actimmune, Tezspire |
| Optinose US, INC. | $26,828.39 | 2019-2023 | |
| Repro Med Systems INC | $25,358.73 | 2020-2022 | |
| Leo Pharma INC. | $22,398.38 | 2022-2025 | Anzupgo, Adbry |
| Csl Behring | $21,260.40 | 2019-2025 | Hizentra, Andembry |
| Insmed, INC. | $19,803.66 | 2025 | Arikayce, Brinsupri |
| Ionis Pharmaceuticals, INC. | $16,488.88 | 2025 | Dawnzera, Donidalorsen |
| Leadiant Biosciences, INC. | $16,361.87 | 2019-2021 | |
| Chiesi USA, INC. | $14,648.53 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $9,932.08 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $9,653.56 | 2019-2023 | Proair Digihaler |
| Biocare, INC. | $9,000.00 | 2023 | |
| Octapharma USA, INC. | $8,259.09 | 2019-2025 | Cutaquig, Panzyga |
| Astrazeneca Pharmaceuticals Lp | $8,183.88 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Gc Biopharma USA, INC. | $7,322.92 | 2024-2025 | Alyglo, Alyglo |
| Alk-Abello, INC | $7,285.49 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Regeneron Pharmaceuticals, INC. | $7,147.89 | 2019-2025 | Dupixent |
| Kedrion Biopharma, INC. | $6,482.52 | 2022-2025 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Koru Medical Systems, INC. | $6,232.00 | 2025 | |
| Grifols Shared Services North America, INC. | $5,438.85 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Sanofi US Services INC. | $5,400.00 | 2024-2025 | |
| Genentech, INC. | $4,072.81 | 2019-2024 | Xolair |
| Biocryst Pharmaceuticals, INC. | $3,812.25 | 2020-2025 | Orladeyo |
| Kedrion Biopharma INC. | $3,531.12 | 2021 | |
| Genentech USA, INC. | $2,325.88 | 2019-2024 | Xolair |
| Mitsubishi Tanabe Pharma Development America, INC. | $1,300.00 | 2022 | |
| Blueprint Medicines Corporation | $1,091.97 | 2023-2024 | Ayvakit |
| Fff Enterprises, INC. | $1,000.00 | 2022 | |
| Tersera Therapeutics LLC | $924.85 | 2022-2024 | Quzyttir |
| Bio Products Laboratory USA, INC. | $774.09 | 2019-2023 | Coagadex, Gammaplex |
| F. Hoffmann-La Roche Ag | $669.25 | 2019-2022 | |
| Kyowa Kirin, INC. | $608.72 | 2024-2025 | |
| Galderma Laboratories, L.P. | $565.87 | 2022-2025 | Nemluvio |
| Dermavant Sciences, INC. | $415.74 | 2023-2024 | Vtama |
| Kaleo, INC. | $354.29 | 2019-2024 | Auvi-Q |
| Advanced Respiratory, INC | $326.55 | 2021 | |
| Greer Laboratories, INC. | $231.21 | 2022-2025 | Oralair |
| Ars Pharmaceuticals Operations, INC. | $186.97 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.02 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $125.00 | 2022 | |
| Aimmune Therapeutics, INC. | $123.72 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $118.13 | 2023 | Zeposia |
| Ucb, INC. | $116.05 | 2025 | Bimzelx |
| Sobi, INC | $101.56 | 2019 | |
| Argenx US, INC. | $98.04 | 2023 | Vyvgart |
| Organon LLC | $85.36 | 2025 | Vtama |
| Hospira, INC. | $73.92 | 2022-2023 | |
| Aero US INC | $52.87 | 2025 | Aerogen Solo Nebulizer System, Aerogen Solo; Aerogen Ultra, Aerogen Usb Controller System |
| Phadia US INC. | $30.45 | 2020-2021 | |
| Cycle Pharmaceuticals INC | $19.11 | 2025 | Sajazir |
| Azurity Pharmaceuticals, INC. | $14.73 | 2025 | Alvesco |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$144,751.18 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Geng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.